Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 4/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1197437 | 0.99 | HTR1F (0.44) | HTR1FACKR3MAPTNPC1RAB9A | |
| SCHEMBL12020804 | 0.91 | HTR1F (0.46) | HTR1FACKR3MAPTNPC1RAB9A | |
| SCHEMBL12020888 | 0.90 | HTR1F (0.47) | HTR1FACKR3MAPTHPGDUBE2M | |
| Hydrochloric Acid SCHEMBL1198146 | 0.90 | HTR1F (0.45) | HTR1FACKR3MAPTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL1197923 | 0.90 | HTR1F (0.46) | HTR1FACKR3MAPTHPGDUBE2M | |
| SCHEMBL12878366 | 0.88 | HTR1F (0.56) | HTR1FMAPTHPGDKMT2ARXFP1 | |
| Hydrochloric Acid SCHEMBL1198027 | 0.88 | HTR1F (0.55) | HTR1FMAPTHPGDKMT2ARXFP1 | |
| SCHEMBL27646118 | 0.87 | HTR1F (0.46) | HTR1FMAPTHPGDKMT2ASORT1 | |
| SCHEMBL12020985 | 0.86 | HTR1F (0.50) | HTR1FACKR3MAPT | |
| Hydrochloric Acid SCHEMBL1197813 | 0.85 | HTR1F (0.49) | HTR1FACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663971-B1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-7291632-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291632-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | HTR1F, HTR1A, HTR3B | HTR1F 1/4885ACKR3 103/4885MAPT 3600/4885 |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | HTR1F, HTR1A, HTR3B | HTR1F 1/4885ACKR3 103/4885MAPT 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.